- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04761679
Nasal Bridge Pressure Injury Prevention
May 13, 2022 updated by: Columbia University
Nasal Bridge Pressure Injury Prevention Using Protective Dressing and Halyard Fluidshield N95 Mask
The primary goal of this study is to explore whether applying the Mepilex foam on the nasal bridge directly between the skin and the N95 mask will prevent nasal bridge pressure injury among nursing staff, secondary to long-term ( >8+ hours) wear time.
The secondary goal is to evaluate if using the Mepilex maintains the seal of the mask.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Nurses use the N95 Mask as part of the personal protective equipment (PPE) when caring for patients with COVID-19.
The N95 mask covers their nose and mouth with a tight seal.
Nurses wear the mask for more than 8 hours per day, as a result they are at increased risk for skin injury on the nasal bridge.
Mepliex is foam dressing which has been used to prevent pressure injuries to the skin.
This study will evaluate if using Mepilex or band-aid on the nasal bridge of the nurses who wear the N95 for more than 8 hours decreases the potential for skin injury.
In addition, the investigators will test if the Mepilex or band-aid also maintains the seal of the mask.
Maintaining the seal is important to ensure that the nurse is not exposed to the virus.
The investigators will be working with nurses who do not directly take care of COVID-19 patients to ensure the safety of all participants.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center/NYP
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The sample will consist of nursing staff working on non-COVID units, including: Medical Surgical Units, Operating Rooms or Ambulatory Care- Labor and Delivery Unit, Maternity Unit and Medical Oncology Unit, at NewYork-Presbyterian (NYP) Lawrence Hospital.
Exclusion Criteria:
- Exclusion Criteria: A score on > 5 the COVID Anxiety Scale. The scale has 4 questions with 5 possible options (rated 1 - 5), to evaluate the effect of COVID19 on the individual. The lowest possible score is 0, the highest possible score is 20. A score of 5 states that the individual experiences COVID19 related anxiety for 'Rarely' or 'Not at All". Excluding participants with a score of > 5 will prevent unnecessary harm to study participants or exacerbate symptoms of anxiety.
- Nurses working in the Emergency Department, Intensive Care Unit or a unit with a focus on the exposed COVID-19 population
- Non-clinical nurses, volunteer or agency registered nurses
- Known history of skin breakdown or damage to the nasal bridge
- History of skin-related conditions including (acne vulgaris, Psoriasis, Herpetic lesions to mouth, nasal areas)
- History of surgery to nasal bridge
- Pregnant nurses in their third trimester
- History of respiratory extended respirator use in addition to the hours collected in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Group
|
Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask.
|
No Intervention: Control Group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Pressure Injury Prevention
Time Frame: 48 hours
|
Researchers will count the number of participants with and without injury on the nasal bridge directly between the skin and the N95 mask
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants that Maintain Mask Seal Integrity
Time Frame: 12 hours
|
Researchers will assess the integrity of the N95 mask seal using both interventions - Mepilex and Band-Aid.
The number of participants with acceptable seal according to the Fit Test will be counted
|
12 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hazel Holder, MSN, RN, ACCNS-AG, CCRN, Columbia University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 23, 2021
Primary Completion (Actual)
January 4, 2022
Study Completion (Actual)
January 4, 2022
Study Registration Dates
First Submitted
February 16, 2021
First Submitted That Met QC Criteria
February 16, 2021
First Posted (Actual)
February 21, 2021
Study Record Updates
Last Update Posted (Actual)
May 19, 2022
Last Update Submitted That Met QC Criteria
May 13, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAT2889
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Coded participant data will be made available to future researchers with a goal to replicate this study and add to the body of nursing knowledge
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pressure Ulcer of Skin
-
Bayside HealthCompletedLength of ICU Stay | Pressure Ulcer, Area | Pressure Ulcer, Grade | Albumin Level | Risk ScoreAustralia
-
The Hong Kong Polytechnic UniversityCompletedPrevention of Pressure UlcersChina
-
The Cleveland ClinicRecruitingStage 1 Pressure Ulcer | Stage 2 Pressure UlcerUnited States, Austria
-
University GhentCare of Sweden ABCompletedPressure Ulcer | Pressure Injury | Pressure Ulcer, Buttock | Pressure SoreBelgium
-
Our Lady of Maryknoll HospitalWong Tai Sin HospitalUnknownPressure Ulcers Stage III | Pressure Ulcer, Stage IVHong Kong
-
Maltepe UniversityRecruitingPressure Ulcer, Heel | Plantar Flexion Contracture of Tarsometatarsal JointTurkey
-
Integra LifeSciences CorporationSt Vincent's HospitalCompletedPressure Ulcer | Pressure Ulcers Stage III | Pressure Ulcer, Stage IVUnited States
-
Istituto Ortopedico RizzoliCompleted
-
Yonsei UniversityUnknownPostoperative Pressure Ulcer
-
Charite University, Berlin, GermanyCompletedPressure Ulcer PreventionGermany
Clinical Trials on Applying the Mepilex foam
-
Calvary Hospital, Bronx, NYIntegra LifeSciences CorporationCompletedNeuropathic Diabetic Foot UlcerUnited States
-
Next Science TMAdvancing the Zenith of HealthcareTerminated
-
Belgium Health Care Knowledge CentreCompleted
-
Vancouver Coastal HealthUniversity of British ColumbiaUnknown
-
Eskisehir Osmangazi UniversityRecruiting
-
Birken AGCompletedInherited Epidermolysis BullosaGermany
-
Calvary Hospital, Bronx, NYSuspended
-
Unity Health TorontoRoche Pharma AGCompletedMultiple SclerosisChile, Argentina, Canada, Spain
-
Istanbul University - Cerrahpasa (IUC)CompletedMultisensory StimulationTurkey
-
Tactile Systems Technology, Inc.Terminated